2024 Q4 Form 10-Q Financial Statement
#000200791924000058 Filed on November 14, 2024
Income Statement
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
Revenue | $0.00 | $120.0K | |
YoY Change | -100.0% | -57.14% | |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $7.804M | $7.850M | |
YoY Change | -0.59% | 48.39% | |
% of Gross Profit | |||
Research & Development | $38.89M | $37.80M | |
YoY Change | 2.89% | 53.16% | |
% of Gross Profit | |||
Depreciation & Amortization | $760.0K | $300.0K | |
YoY Change | 153.33% | -3.23% | |
% of Gross Profit | |||
Operating Expenses | $46.80M | $45.95M | |
YoY Change | 1.84% | 51.75% | |
Operating Profit | -$46.80M | -$45.83M | |
YoY Change | 2.12% | ||
Interest Expense | $2.892M | -$5.830M | |
YoY Change | -149.61% | 9.18% | |
% of Operating Profit | |||
Other Income/Expense, Net | $2.933M | -$140.0K | |
YoY Change | -2195.0% | -800.0% | |
Pretax Income | -$43.86M | -$51.79M | |
YoY Change | -15.3% | 46.59% | |
Income Tax | $0.00 | $0.00 | |
% Of Pretax Income | |||
Net Earnings | -$43.86M | -$51.79M | |
YoY Change | -15.3% | 46.59% | |
Net Earnings / Revenue | -43158.33% | ||
Basic Earnings Per Share | -$2.84 | -$4.39 | |
Diluted Earnings Per Share | -$2.84 | -$1.10 | |
COMMON SHARES | |||
Basic Shares Outstanding | 14.48M shares | 14.48M shares | 11.79M shares |
Diluted Shares Outstanding | 15.47M shares | 11.79M shares |
Balance Sheet
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $196.3M | $337.3M | |
YoY Change | -41.79% | 130.87% | |
Cash & Equivalents | $196.3M | $337.3M | |
Short-Term Investments | |||
Other Short-Term Assets | $748.0K | $25.60M | |
YoY Change | -97.08% | 245.95% | |
Inventory | |||
Prepaid Expenses | |||
Receivables | $455.0K | $300.0K | |
Other Receivables | $672.0K | $0.00 | |
Total Short-Term Assets | $207.4M | $363.3M | |
YoY Change | -42.9% | 136.22% | |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $6.879M | $6.300M | |
YoY Change | 9.19% | -20.25% | |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $6.712M | $3.200M | |
YoY Change | 109.75% | 0.0% | |
Total Long-Term Assets | $15.12M | $9.400M | |
YoY Change | 60.81% | -15.32% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $207.4M | $363.3M | |
Total Long-Term Assets | $15.12M | $9.400M | |
Total Assets | $222.6M | $372.7M | |
YoY Change | -40.28% | 126.02% | |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $12.37M | $7.900M | |
YoY Change | 56.58% | -8.14% | |
Accrued Expenses | $29.89M | $27.90M | |
YoY Change | 7.13% | 70.12% | |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $44.10M | $35.80M | |
YoY Change | 23.17% | 40.94% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $205.7M | |
YoY Change | -100.0% | 20.43% | |
Other Long-Term Liabilities | $0.00 | $1.600M | |
YoY Change | -100.0% | -56.76% | |
Total Long-Term Liabilities | $0.00 | $207.3M | |
YoY Change | -100.0% | 18.8% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $44.10M | $35.80M | |
Total Long-Term Liabilities | $0.00 | $207.3M | |
Total Liabilities | $44.10M | $243.1M | |
YoY Change | -81.86% | 21.61% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$58.30M | ||
YoY Change | |||
Common Stock | $1.000K | ||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $178.5M | $129.6M | |
YoY Change | |||
Total Liabilities & Shareholders Equity | $222.6M | $372.7M | |
YoY Change | -40.28% | 126.02% |
Cashflow Statement
Concept | 2024 Q4 | 2024 Q3 | 2023 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$43.86M | -$51.79M | |
YoY Change | -15.3% | 46.59% | |
Depreciation, Depletion And Amortization | $760.0K | $300.0K | |
YoY Change | 153.33% | -3.23% | |
Cash From Operating Activities | -$30.28M | -$54.25M | |
YoY Change | -44.18% | 75.91% | |
INVESTING ACTIVITIES | |||
Capital Expenditures | $247.0K | $810.0K | |
YoY Change | -69.51% | -4150.0% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | -$247.0K | -$810.0K | |
YoY Change | -69.51% | -4150.0% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $200.0M | ||
YoY Change | 39904.0% | ||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 199.9M | |
YoY Change | -100.0% | 39878.0% | |
NET CHANGE | |||
Cash From Operating Activities | -30.28M | -54.25M | |
Cash From Investing Activities | -247.0K | -810.0K | |
Cash From Financing Activities | 0.000 | 199.9M | |
Net Change In Cash | -30.53M | 144.8M | |
YoY Change | -121.08% | -577.67% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$30.28M | -$54.25M | |
Capital Expenditures | $247.0K | $810.0K | |
Free Cash Flow | -$30.53M | -$55.06M | |
YoY Change | -44.56% | 78.65% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0002007919 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
99-0613523 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
11025 N. Torrey Pines Road | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 140 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
La Jolla | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92037 | ||
dei |
City Area Code
CityAreaCode
|
(858) | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 | ||
dei |
Trading Symbol
TradingSymbol
|
INBX | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2024Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
14475904 | shares |
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
196332000 | usd |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
277924000 | usd |
us-gaap |
Revenues
Revenues
|
166000 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
170376000 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
109549000 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
111244000 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
21549000 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
281620000 | usd | |
us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
0 | usd | |
us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
23617000 | usd | |
inhibrx |
Interest Income Nonoperating
InterestIncomeNonoperating
|
8937000 | usd | |
inhibrx |
Interest Income Nonoperating
InterestIncomeNonoperating
|
7221000 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
15000 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-422000 | usd | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2016959000 | usd | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-16818000 | usd | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
1735439000 | usd | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-147750000 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
1735437000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-147757000 | usd | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
119.04 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-13.19 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
117.09 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-13.19 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14578000 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
11201000 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14821000 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
11201000 | shares | |
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
CY2024Q2 | inhibrx |
Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
|
0.25 | |
dei |
Entity Registrant Name
EntityRegistrantName
|
INHIBRX BIOSCIENCES, INC. | ||
dei |
Local Phone Number
LocalPhoneNumber
|
795-4220 | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
CY2024Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
9987000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16656000 | usd |
CY2024Q3 | us-gaap |
Assets Current
AssetsCurrent
|
207446000 | usd |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
295358000 | usd |
CY2024Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6879000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6419000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1525000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2952000 | usd |
CY2024Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
6712000 | usd |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
3164000 | usd |
CY2024Q3 | us-gaap |
Assets
Assets
|
222562000 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
307893000 | usd |
CY2024Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
12370000 | usd |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10954000 | usd |
CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
29890000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
43295000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1835000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2063000 | usd |
CY2024Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
44095000 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
56312000 | usd |
CY2024Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
206968000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1110000 | usd |
CY2024Q3 | us-gaap |
Liabilities
Liabilities
|
44095000 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
264390000 | usd |
CY2024Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2024Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
CY2024Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2024Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2024Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | shares |
CY2024Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
14475904 | shares |
CY2024Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
14475904 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47369511 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47369511 | shares |
CY2024Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
5000 | usd |
CY2024Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
236733000 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
657232000 | usd |
CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-58267000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-613734000 | usd |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
178467000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
43503000 | usd |
CY2024Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
222562000 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
307893000 | usd |
CY2024Q3 | us-gaap |
Revenues
Revenues
|
0 | usd |
CY2023Q3 | us-gaap |
Revenues
Revenues
|
119000 | usd |
us-gaap |
Revenues
Revenues
|
100000 | usd | |
CY2024Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
38893000 | usd |
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
38057000 | usd |
CY2024Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7904000 | usd |
CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7889000 | usd |
CY2024Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
46797000 | usd |
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
45946000 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
131098000 | usd | |
CY2024Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-46797000 | usd |
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-45827000 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-281520000 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-130932000 | usd | |
CY2024Q3 | us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
0 | usd |
CY2023Q3 | us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
0 | usd |
us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
2021498000 | usd | |
CY2024Q3 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
0 | usd |
CY2023Q3 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
8149000 | usd |
us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
13491000 | usd | |
CY2024Q3 | inhibrx |
Interest Income Nonoperating
InterestIncomeNonoperating
|
2892000 | usd |
CY2023Q3 | inhibrx |
Interest Income Nonoperating
InterestIncomeNonoperating
|
2324000 | usd |
CY2024Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
41000 | usd |
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-135000 | usd |
CY2024Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2933000 | usd |
CY2023Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5960000 | usd |
CY2024Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-43864000 | usd |
CY2023Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-51787000 | usd |
CY2024Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2023Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | usd |
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43864000 | usd |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-51789000 | usd |
CY2024Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.84 | |
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.39 | |
CY2024Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.84 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.39 | |
CY2024Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15468000 | shares |
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
11788000 | shares |
CY2024Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15468000 | shares |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
11788000 | shares |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
43503000 | usd |
CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6397000 | usd |
CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
40378000 | usd |
CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-78710000 | usd |
CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11568000 | usd |
CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
46174000 | usd |
CY2024Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
31300000 | usd |
CY2024Q2 | us-gaap |
Stockholders Equity Note Spinoff Transaction
StockholdersEquityNoteSpinoffTransaction
|
-1743729000 | usd |
CY2024Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
16042000 | usd |
CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1858011000 | usd |
CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
219366000 | usd |
CY2024Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2965000 | usd |
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43864000 | usd |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
178467000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58057000 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5636000 | usd |
CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
356000 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-48916000 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15133000 | usd |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6253000 | usd |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
854000 | usd |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-47052000 | usd |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-24812000 | usd |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6530000 | usd |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
21000 | usd |
CY2023Q3 | inhibrx |
Stock And Pre Funded Warrants Issued During Period Value
StockAndPreFundedWarrantsIssuedDuringPeriodValue
|
199645000 | usd |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-51789000 | usd |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
129595000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
1735437000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-147757000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1596000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
893000 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
2065000 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
3652000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
55536000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18419000 | usd | |
inhibrx |
Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
|
1427000 | usd | |
inhibrx |
Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
|
1309000 | usd | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-12000 | usd | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-3000 | usd | |
inhibrx |
Nonmonetary Transaction Gain Loss Recognized On Transfer Net
NonmonetaryTransactionGainLossRecognizedOnTransferNet
|
1998809000 | usd | |
inhibrx |
Nonmonetary Transaction Gain Loss Recognized On Transfer Net
NonmonetaryTransactionGainLossRecognizedOnTransferNet
|
0 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-323000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
88000 | usd | |
us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
672000 | usd | |
us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
-14000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-377000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
19268000 | usd | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
3548000 | usd | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
21022000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-801000 | usd | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
35883000 | usd | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
8678000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-1338000 | usd | |
us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-1376000 | usd | |
inhibrx |
Increase Decrease Contract With Customer Liability Current
IncreaseDecreaseContractWithCustomerLiabilityCurrent
|
0 | usd | |
inhibrx |
Increase Decrease Contract With Customer Liability Current
IncreaseDecreaseContractWithCustomerLiabilityCurrent
|
-166000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-150689000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-136488000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2581000 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1151000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2581000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1151000 | usd | |
us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | usd | |
us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
200000000 | usd | |
inhibrx |
Payments Of Private Placement Costs
PaymentsOfPrivatePlacementCosts
|
0 | usd | |
inhibrx |
Payments Of Private Placement Costs
PaymentsOfPrivatePlacementCosts
|
130000 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
71678000 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1231000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
71678000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
201101000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-81592000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
63462000 | usd | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
277924000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
273865000 | usd |
CY2024Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
196332000 | usd |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
337327000 | usd |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
6000 | usd | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
108000 | usd | |
inhibrx |
Private Placement Costs Incurred During Noncash Or Partial Noncash Transaction
PrivatePlacementCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | usd | |
inhibrx |
Private Placement Costs Incurred During Noncash Or Partial Noncash Transaction
PrivatePlacementCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
225000 | usd | |
CY2024Q2 | inhibrx |
Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
|
0.92 | |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Cash Price Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
|
30.00 | |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare
|
1 | right |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Cash Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
|
5.00 | |
CY2024Q2 | inhibrx |
Merger Exchange Ratio
MergerExchangeRatio
|
4 | |
CY2024Q2 | inhibrx |
Merger Ownership Percentage
MergerOwnershipPercentage
|
0.08 | |
CY2024Q1 | us-gaap |
Business Combination Consideration Transferred Other1
BusinessCombinationConsiderationTransferredOther1
|
68000000 | usd |
us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
2000000000.0 | usd | |
us-gaap |
Nonmonetary Transaction Gain Loss Recognized On Transfer
NonmonetaryTransactionGainLossRecognizedOnTransfer
|
2021498000 | usd | |
CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-58300000 | usd |
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
196300000 | usd |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.</span></div> | ||
CY2024Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
0 | usd |
CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
0 | usd |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
243000 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
910000 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1679000 | shares | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
CY2024Q3 | inhibrx |
Clinical Trails Prepaid Expense Current
ClinicalTrailsPrepaidExpenseCurrent
|
4435000 | usd |
CY2023Q4 | inhibrx |
Clinical Trails Prepaid Expense Current
ClinicalTrailsPrepaidExpenseCurrent
|
5409000 | usd |
CY2024Q3 | inhibrx |
Clinical Drug Substance And Product Manufacturing Prepaid Expense Current
ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent
|
3055000 | usd |
CY2023Q4 | inhibrx |
Clinical Drug Substance And Product Manufacturing Prepaid Expense Current
ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent
|
9888000 | usd |
CY2024Q3 | inhibrx |
Prepaid License Current
PrepaidLicenseCurrent
|
1092000 | usd |
CY2023Q4 | inhibrx |
Prepaid License Current
PrepaidLicenseCurrent
|
728000 | usd |
CY2024Q3 | inhibrx |
Outside Research And Development Services Prepaid Expense Current
OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent
|
657000 | usd |
CY2023Q4 | inhibrx |
Outside Research And Development Services Prepaid Expense Current
OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent
|
265000 | usd |
CY2024Q3 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
748000 | usd |
CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
366000 | usd |
CY2024Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
9987000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16656000 | usd |
CY2024Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
15095000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13106000 | usd |
CY2024Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8216000 | usd |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6687000 | usd |
CY2024Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6879000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6419000 | usd |
CY2024Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
760000 | usd |
CY2023Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
304000 | usd |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1596000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
893000 | usd | |
CY2024Q3 | inhibrx |
Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
|
14853000 | usd |
CY2023Q4 | inhibrx |
Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
|
9224000 | usd |
CY2024Q3 | inhibrx |
Accrued Clinical Drug Substance And Product Manufacturing Current
AccruedClinicalDrugSubstanceAndProductManufacturingCurrent
|
1276000 | usd |
CY2023Q4 | inhibrx |
Accrued Clinical Drug Substance And Product Manufacturing Current
AccruedClinicalDrugSubstanceAndProductManufacturingCurrent
|
22805000 | usd |
CY2024Q3 | inhibrx |
Accrued Outside Research And Development Other Current
AccruedOutsideResearchAndDevelopmentOtherCurrent
|
5054000 | usd |
CY2023Q4 | inhibrx |
Accrued Outside Research And Development Other Current
AccruedOutsideResearchAndDevelopmentOtherCurrent
|
1129000 | usd |
CY2024Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6466000 | usd |
CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6506000 | usd |
CY2024Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1883000 | usd |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
780000 | usd |
CY2024Q3 | inhibrx |
Accrued Interest Expense Current
AccruedInterestExpenseCurrent
|
0 | usd |
CY2023Q4 | inhibrx |
Accrued Interest Expense Current
AccruedInterestExpenseCurrent
|
2348000 | usd |
CY2024Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
358000 | usd |
CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
503000 | usd |
CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
29890000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
43295000 | usd |
CY2024Q2 | inhibrx |
Debt Instrument Balloon Payment Write Off
DebtInstrumentBalloonPaymentWriteOff
|
18000000 | usd |
CY2024Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | shares |
CY2024Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
15000000 | shares |
CY2024Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
14475904 | shares |
CY2024Q2 | inhibrx |
Merger Exchange Ratio
MergerExchangeRatio
|
4 | |
CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
13316140 | shares |
CY2024Q2 | inhibrx |
Merger Ownership Percentage
MergerOwnershipPercentage
|
0.08 | |
CY2024Q2 | us-gaap |
Stock Or Units Available For Distributions
StockOrUnitsAvailableForDistributions
|
1157926 | shares |
CY2024Q2 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
1838 | shares |
CY2024Q2 | us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
2746454 | shares |
CY2024Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.0001 | |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Contingent Value Right Per Warrant
ClassOfWarrantOrRightContingentValueRightPerWarrant
|
1 | right |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Contingent Value Right Per Warrant Value
ClassOfWarrantOrRightContingentValueRightPerWarrantValue
|
5.00 | |
CY2024Q2 | inhibrx |
Merger Exchange Ratio
MergerExchangeRatio
|
4 | |
CY2024Q3 | inhibrx |
Class Of Warrant Or Right Purchase Price Of Warrants Or Rights
ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
|
991849 | shares |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Contingent Value Right Per Warrant
ClassOfWarrantOrRightContingentValueRightPerWarrant
|
1 | right |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Contingent Value Right Per Warrant Value
ClassOfWarrantOrRightContingentValueRightPerWarrantValue
|
5.00 | |
CY2024Q2 | inhibrx |
Merger Exchange Ratio
MergerExchangeRatio
|
4 | |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
|
35.00 | |
CY2024Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | shares |
CY2024Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4992000 | shares |
CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
13789000 | shares |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
65300000 | usd | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1300000 | usd | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
42500000 | usd | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
19000000.0 | usd | |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Exercise Price
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice
|
35.00 | |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Cash Price Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
|
30.00 | |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare
|
1 | right |
CY2024Q2 | inhibrx |
Share Based Payment Arrangement Option Exercise Price Range Settled Contingent Value Right Cash Per Common Share
ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
|
5.00 | |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
|
35.00 | |
CY2024Q2 | inhibrx |
Class Of Warrant Or Right Cancelled Threshold Exercise Price
ClassOfWarrantOrRightCancelledThresholdExercisePrice
|
35.00 | |
CY2024Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1800000 | usd |
CY2024Q2 | inhibrx |
Merger Exchange Ratio Pro Rate Basis Percentage
MergerExchangeRatioProRateBasisPercentage
|
0.92 | |
CY2024Q2 | inhibrx |
Merger Ownership Percentage
MergerOwnershipPercentage
|
0.08 | |
CY2024Q2 | us-gaap |
Stock Or Units Available For Distributions
StockOrUnitsAvailableForDistributions
|
1157926 | shares |
CY2017Q3 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P7Y | |
CY2017Q3 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
CY2017Q3 | inhibrx |
Lessee Operating Lease Initial Base Rent Expense Per Month
LesseeOperatingLeaseInitialBaseRentExpensePerMonth
|
100000 | usd |
CY2017Q3 | inhibrx |
Lessee Operating Lease Annual Escalations
LesseeOperatingLeaseAnnualEscalations
|
0.02 | |
CY2019Q2 | inhibrx |
Lessee Operating Lease Initial Base Rent Expense Per Month
LesseeOperatingLeaseInitialBaseRentExpensePerMonth
|
30000 | usd |
CY2019Q2 | inhibrx |
Lessee Operating Lease Annual Escalations
LesseeOperatingLeaseAnnualEscalations
|
0.02 | |
CY2024Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1525000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2952000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1835000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2063000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1110000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1835000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3173000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
900000 | usd |
CY2023Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
900000 | usd |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
2500000 | usd | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
2600000 | usd | |
CY2024Q3 | inhibrx |
Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
|
400000 | usd |
CY2023Q3 | inhibrx |
Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
|
500000 | usd |
inhibrx |
Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
|
1500000 | usd | |
inhibrx |
Operating Lease Payments Included In Measurement Of Lease Liability
OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability
|
1600000 | usd | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P0Y9M18D | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P1Y6M | |
CY2024Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.082 | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.082 | |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
755000 | usd |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1137000 | usd |
CY2024Q3 | inhibrx |
Lessee Operating Lease Liability To Be Paid After Year One
LesseeOperatingLeaseLiabilityToBePaidAfterYearOne
|
0 | usd |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1892000 | usd |
CY2024Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
57000 | usd |
CY2024Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1835000 | usd |
CY2024Q3 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
CY2024Q3 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |